UNSPSC 51332862: Perphenazine decanoate

This classification denotes an antipsychotic agent C31H44ClN3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RHE0987NHE, chemically known as decanoic acid, 2-(4-(3-(2-chloro-10h-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester, but more generally known as perphenazine decanoate, which bears US NIH Compound Identifier 62873. European Medicines Agency schedules Perphenazine decanoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03716MIG.

Most nations, for tariff and trade purposes, schedule perphenazine decanoate under HS 29343090 and SITC 51578. As of Q4 2014, PERPHENAZINE DECANOATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3CCCCC3SC4C2CC(CC4)CL.

UNSPSC 51332862 Perphenazine decanoate is a Commodity code that in recent state and local procurement activity covers pharmaceutical products and emergency health supplies procured through competitive bidding and cooperative purchasing arrangements. The code nominally describes a specific antipsychotic medication, but the actual recent opportunities under this code span broader pharmaceutical and health-supply categories, including naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products. State and local issuing bodies soliciting under this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). These buyers are acquiring pharmaceutical inventory and emergency health products for distribution to community health facilities, pharmacy benefit programs, and participating state and local government agencies.

Recent procurement activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (IFB60459723LAS) on June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with response due July 26, 2023. The Texas HHS Commission posted an RFI (HHS0017013) on April 3, 2026 to gather vendor capabilities for a Direct-to-Manufacturer Prescriptions program under its Therapeutic Pharmacy Initiative, focused on establishing direct relationships between state pharmacy benefit programs and pharmaceutical manufacturers. The Minnesota Department of Administration, through the MMCAP cooperative purchasing vehicle, issued an RFP (S1070000015802) on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026, establishing contracts effective July 1, 2026 with distribution through three authorized wholesalers serving participating state and local government facilities in Minnesota and Oregon.